Stock Traders Buy High Volume of Call Options on Cerevel Therapeutics (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) saw unusually large options trading activity on Wednesday. Traders purchased 7,125 call options on the company. This is an increase of approximately 399% compared to the average volume of 1,428 call options.

Insider Buying and Selling

In other Cerevel Therapeutics news, Director N Anthony Coles sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $41.18, for a total transaction of $1,029,500.00. Following the completion of the sale, the director now directly owns 25,928 shares of the company’s stock, valued at $1,067,715.04. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Headlands Technologies LLC bought a new stake in Cerevel Therapeutics during the first quarter valued at about $26,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Cerevel Therapeutics during the 4th quarter valued at approximately $71,000. Centaurus Financial Inc. purchased a new position in Cerevel Therapeutics in the 4th quarter worth approximately $119,000. GAM Holding AG bought a new position in Cerevel Therapeutics in the 4th quarter worth approximately $212,000. Finally, Virtu Financial LLC purchased a new stake in Cerevel Therapeutics during the 4th quarter valued at approximately $246,000. Hedge funds and other institutional investors own 87.73% of the company’s stock.

Cerevel Therapeutics Stock Down 2.3 %

CERE stock opened at $40.30 on Thursday. The business’s 50-day moving average price is $41.46 and its 200-day moving average price is $41.82. The stock has a market cap of $7.34 billion, a P/E ratio of -14.76 and a beta of 1.40. The company has a quick ratio of 10.22, a current ratio of 10.22 and a debt-to-equity ratio of 0.60. Cerevel Therapeutics has a twelve month low of $19.59 and a twelve month high of $43.59.

Cerevel Therapeutics (NASDAQ:CERE) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.12). On average, equities research analysts forecast that Cerevel Therapeutics will post -2.59 EPS for the current year.

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.